Loading...
Market
Will Merck announce a new clinical trial for CN201 therapy by June 30, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press release from Merck
Story
Merck to Acquire CN201 Therapy from Curon for $700M, Plus Earnouts
Aug 9, 2024, 10:55 AM
Merck has announced its acquisition of the investigational B-cell depletion therapy CN201 from Curon Biopharmaceutical. The deal includes an upfront payment of $700 million in cash, with potential earnouts of up to $600 million. This acquisition is part of Merck's strategy to expand its pipeline, particularly in the areas of B-cell malignancies and autoimmune diseases. The therapy, described as a novel investigational bispecific antibody, is expected to enhance Merck's offerings in these therapeutic areas.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
